Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124


Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer.

Cheng YW, Idrees K, Shattock R, Khan SA, Zeng Z, Brennan CW, Paty P, Barany F.

Int J Cancer. 2010 Aug 1;127(3):568-77. doi: 10.1002/ijc.25086.


Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.

Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP.

Cancer Res. 2002 Nov 15;62(22):6442-6.


Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients.

Tian F, Tang Z, Song G, Pan Y, He B, Bao Q, Wang S.

Mol Med Rep. 2012 Jun;5(6):1536-40. doi: 10.3892/mmr.2012.833. Epub 2012 Mar 13.


Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Baba Y, Nosho K, Shima K, Huttenhower C, Tanaka N, Hazra A, Giovannucci EL, Fuchs CS, Ogino S.

Gastroenterology. 2010 Dec;139(6):1855-64. doi: 10.1053/j.gastro.2010.07.050. Epub 2010 Aug 2.


Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma.

Honda S, Arai Y, Haruta M, Sasaki F, Ohira M, Yamaoka H, Horie H, Nakagawara A, Hiyama E, Todo S, Kaneko Y.

Br J Cancer. 2008 Dec 2;99(11):1891-9. doi: 10.1038/sj.bjc.6604754. Epub 2008 Oct 28.


Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site.

Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR.

Hum Mol Genet. 2003 Mar 1;12(5):535-49.


Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system.

Pan Y, He B, Chen J, Sun H, Deng Q, Wang F, Ying H, Liu X, Lin K, Peng H, Xie H, Wang S.

Int J Oncol. 2015 Nov;47(5):1881-9. doi: 10.3892/ijo.2015.3181. Epub 2015 Sep 23.


Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.

Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A.

Mol Cancer Res. 2006 Apr;4(4):283-92.


H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway.

Gao T, He B, Pan Y, Gu L, Chen L, Nie Z, Xu Y, Li R, Wang S.

Clin Transl Oncol. 2014 Apr;16(4):410-7. doi: 10.1007/s12094-013-1098-x. Epub 2013 Aug 13.


Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer.

Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A.

Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):591-6. Epub 2000 Dec 19.


Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene.

Cruz-Correa M, Zhao R, Oviedo M, Bernabe RD, Lacourt M, Cardona A, Lopez-Enriquez R, Wexner S, Cuffari C, Hylind L, Platz E, Cui H, Feinberg AP, Giardiello FM.

Epigenetics. 2009 Feb 16;4(2):114-8. Epub 2009 Feb 27.


Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.

Bjornsson HT, Brown LJ, Fallin MD, Rongione MA, Bibikova M, Wickham E, Fan JB, Feinberg AP.

J Natl Cancer Inst. 2007 Aug 15;99(16):1270-3. Epub 2007 Aug 8.


Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.

Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, Woodfine K, Jagodic M, Nativio R, Dunning A, Moore G, Klenova E, Bingham S, Pharoah PD, Brenton JD, Beck S, Sandhu MS, Murrell A.

Hum Mol Genet. 2008 Sep 1;17(17):2633-43. doi: 10.1093/hmg/ddn163. Epub 2008 Jun 9.


Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.

Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC, Maher ER.

Br J Cancer. 2005 Apr 25;92(8):1574-80.


Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2.

Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T.

Int J Cancer. 2006 Jul 1;119(1):80-3.


Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications.

Belharazem D, Magdeburg J, Berton AK, Beissbarth L, Sauer C, Sticht C, Marx A, Hofheinz R, Post S, Kienle P, Ströbel P.

J Gastroenterol. 2016 Oct;51(10):971-84. doi: 10.1007/s00535-016-1181-5. Epub 2016 Mar 17.


Examination of IGF2 and H19 loss of imprinting in bladder cancer.

Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS.

Cancer Res. 2007 Nov 15;67(22):10753-8.

Supplemental Content

Support Center